Journal of medical & health sciences review.
March 11, 2025
Ahmad Daryani, Muhammad Ali, Usman Ul Haq
Psilocybin, MDMA, and LSD have recently emerged as popular psychedelic substances for use in psychopharmacology in managing various disorders including treatment-resistant depression, PTSD, and anxiety. These substances mainly affect the serotonergic receptors that involve the regulation of consciousness, perceptions, and cognition. These unique alterations in brain connectome show the...
BMC Medical Education
March 5, 2025
Helena Aicher, F Müller, Peter Gasser
11 citations
The growing interest in psychedelic-assisted therapy (PAT) for treating psychiatric disorders such as treatment-resistant depression, PTSD, and anxiety has led to an increasing demand for specialized training. In Switzerland, MDMA, psilocybin, and LSD are applied in the framework of limited medical use as exceptional treatment options since 2014. The Swiss Medical Association for Psychedelic...
The Brown University Psychopharmacology Update
March 3, 2025
The stressors that frontline healthcare workers experienced during the COVID-19 pandemic led to widespread burnout, depression, and post-traumatic stress disorder (PTSD). Based on research showing that psychedelic-assisted therapy led to improvement in symptoms of depression in various populations, investigators conducted a randomized clinical trial to evaluate the effects of psilocybin therapy...
Nature Chemistry
March 1, 2025
Rishab N Iyer, David Favela, Andras Domokos et al.
22 citations
Anecdotal reports and preliminary clinical trials suggest that the psychoactive alkaloid ibogaine and its active metabolite noribogaine have powerful anti-addictive properties, producing long-lasting therapeutic effects across a range of substance use disorders and co-occurring neuropsychiatric diseases such as depression and post-traumatic stress disorder. Here we report a gram-scale,...
Cleveland Clinic Journal of Medicine
March 1, 2025
Franklin King, Brian S. Barnett, Erin Mauney
11 citations
Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymethamphet-amine (MDMA) and psilocybin-may be efficacious for depression, posttraumatic stress disorder, substance use disorders, and other conditions. Therapeutic psychedelic research is advancing steadily, with psilocybin, MDMA, and lysergic acid...
Medical Science
February 25, 2025
Jakub Pudźwa, Kamil Gibczyński, Karol Leśniewski et al.
Objective: The purpose of the following review was to summarize the recent studies on proposed mechanisms of action of psychedelic drugs (psilocybin, MDMA, LSD), their therapeutic potential in mental disorders (depression, PTSD, addictions), and the evaluation of their safety. This review also discusses the barriers to the clinical implementation of these agents. Methodology: The paper combines...
Journal of Bahria University Medical and Dental College
February 24, 2025
Ambreen Kalam, Fazal Ameen Habib
Dear Sir, ‘There is a time for many words, and there is also a time for sleep’ Homer, the Odyssey. A recent systemic review of an aggregated data from 35 empirical studies (N=36,533 subjects) found that 7.6% of the general population experienced at least one Sleep paralysis episode over the course of their life. Higher lifetime prevalence rates were found in students (28.3%) and psychiatric...
Health Problems of Civilization
February 20, 2025
Julia Wójcik, Kacper Wojciech Pamuła, Marcin Cholewa et al.
Psylocybina to psychoaktywny związek chemiczny występujący w grzybach z rodzaju Psilocybe, które zyskały znaczną popularność w ostatniej dekadzie ze względu na ich wpływ na neuroplastyczność, działanie serotoninergiczne oraz zdolność do tworzenia nowych połączeń między obszarami, które komunikowały się wcześniej ze sobą. Celem niniejszego badania jest ocena potencjalnych zastosowań psylocybiny...
Journal of Clinical Medicine
February 20, 2025
Shakila Meshkat, Taha Malik, Jennifer Swainson et al.
3 citations
Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscores the need for alternatives. Psychedelic therapies may rapidly reduce suicide risk. This systematic review evaluates impact of psychedelic therapies on suicide-related outcomes. Methods: A systematic search of MEDLINE, Embase, PsycINFO, and...
General Psychiatry
February 19, 2025
Jérémie Richard, Albert Garcia‐romeu, Jack E Henningfield
7 citations
The United States Food and Drug Administration’s (FDA’s) August 2024 determination that an additional phase III study will be required to consider the approval of midomafetamine for the treatment of post-traumatic stress disorder (PTSD) could delay the potential approval of this promising treatment by several years.